Análisis cuantitativo de paramentos de ladrillo: ejemplos de algunos grandes edificios imperiales en Roma

This paper aims to present some preliminary results of an ongoing study which started from the analysis of the external brick facing of the Aurelianic Walls. The methodology employed was to analyse the brick facing by sampling the brick wall surfaces, drawing consistent areas of 1x1 m2 in CAD, based on rectified photographs. These samples were then measured in detail to make a quantitative-statistical analysis of the elements constituting the brick facings, in order to yield standard parameters which could meaningfully describe their features. In this first part of the work, we tried to compare some of the most important imperial brick buildings, each with its own characteristic features. Sampling has covered the Aurelianic Walls extensively, focusing on the early periods of Aurelian and Honorius. After were sampled brick-faced walls from a Neronian building facing the Valley of the Colosseum; the substructures of the Baths of Trajan; and some sectors of the Domus Tiberiana, towards the north slope of the Palatine Hill.El objetivo de este documento, es presentar resultados de un estudio en curso, comenzando con el análisis de la cortina externa en ladrillos de los muros Aurelianos. Como metodología de estudio, las capas de ladrillos fueron inspeccionadas a través de muestras de sus superficies, seleccionando partes de 1x1m2 dibujados en CAD, utilizando fotos sin distorsión. Dichas muestras, fueron medidas en detalle, para generar análisis de estadísticas cuantitativas de los elementos constituyentes de éstas cortinas, para obtener standars, que pueden describir sus características. En esta primera fase, tratamos de comparar algunas de los más importantes fabricantes de ladrillos imperiales, cada una con características especificas. El muestrario ha cubierto extensivamente los muros aurelianos, concentrándose en los periodos de Aureliano y Honorio. Luego, fueron estudiadas paredes de ladrillos de edificios de época neroniana, frente al valle del Coliseo; subestructuras de las termas de Trajano; sectores de la Domus Tiberiana, en dirección a la falda norte del Palatino

Low spatial autocorrelation in mountain biodiversity data and model residuals

Spatial autocorrelation (SAC) is a common feature of ecological data where observations tend to be more similar at some geographic distance(s) than expected by chance. Despite the implications of SAC for data dependencies, its impact on the performance of species distribution models (SDMs) remains controversial, with reports of both strong and negligible impacts on inference. Yet, no study has comprehensively assessed the prevalence and the strength of SAC in the residuals of SDMs over entire geographic areas. Here, we used a large-scale spatial inventory in the western Swiss Alps to provide a thorough assessment of the importance of SAC for (1) 850 species belonging to nine taxonomic groups, (2) six predictors commonly used for modeling species distributions, and (3) residuals obtained from SDMs fitted with two algorithms with the six predictors included as covariates. We used various statistical tools to evaluate (1) the global level of SAC, (2) the spatial pattern and spatial extent of SAC, and (3) whether local clusters of SAC can be detected. We further investigated the effect of the sampling design on SAC levels. Overall, while environmental predictors expectedly displayed high SAC levels, SAC in biodiversity data was rather low overall and vanished rapidly at a distance of similar to 5-10 km. We found low evidence for the existence of local clusters of SAC. Most importantly, model residuals were not spatially autocorrelated, suggesting that inferences derived from SDMs are unlikely to be affected by SAC. Further, our results suggest that the influence of SAC can be reduced by a careful sampling design. Overall, our results suggest that SAC is not a major concern for rugged mountain landscapes.Peer reviewe

Categorización del estado de conservación de las serpientes de la República Argentina

A más de una década de la primera Lista Roja de herpetofauna amenazada propuesta por la Asociación Herpetológica Argentina (AHA 2000), se recategorizaron las serpientes a partir de nueva información taxonómica, biogeográfica y bio-ecológica, además de modificaciones metodológicas respecto a la evaluación anterior. Mediante la participación de 18 especialistas de toda la Argentina se reevaluaron 136 taxones de serpientes (130 en la anterior) incluyendo varios cambios taxonómicos (8 taxones nuevos para Argentina y 2 sinonimizados), obteniéndose como resultado la inclusión de 49 especies en la lista roja (5 En Peligro, 17 Amenazadas, 27 Vulnerables), 15 Insuficientemente Conocidas y 72 No Amenazadas. En relación con la categorización anterior de la AHA: un taxón descendió de Vulnerable a No Amenazado, 11 No amenazados y 4 Insuficientemente Conocidos fueron elevados a distintas categorías de amenaza, 7 taxones Vulnerables fueron elevados a Amenazados, un taxón fue elevado de Amenazado a En Peligro. De 8 taxones no evaluados en 2000, uno categorizó No Amenazado, 4 Insuficientemente Conocidos, uno Vulnerable y 2 Amenazados. Estas modificaciones son el resultado de: (1) Mayor información sistemática, biogeográfica y bio-ecológica disponible para la evaluación; (2) Cambios en cuanto a las presiones antrópicas sobre las especies o sus hábitats; (3) Modificaciones metodológicas que incluyeron instructivos para aplicar los conceptos, la discusión y consenso entre especialistas y el análisis de las incertidumbres.After more than a decade from the first red list of threatened herpetofauna proposal by the Asociación Herpetológica Argentina (2000), we re-categorized snakes from new taxonomic, biogeographical and bio-ecological information as well as methodological changes in the former evaluation. Through the participation of 18 specialists from all over Argentina, 136 taxa of snakes (130 in the previous) were re-evaluated including several taxonomic changes (8 new taxa added to Argentina, and 2 sinonimies). The results were the inclusion of 49 species in the red list (5 Endangered, 17 Threatened, 27 Vulnerable), 15 Insufficiently Known and 72 Not Threatened. Compared to the former categorization of the AHA: one taxon descended from Vulnerable to Not Threatened, 11 Not Threatened and 4 Insufficiently Known were elevated to different categories of threat, 7 taxa were elevated from Endangered to Vulnerable, one from Vulnerable to Endangered. From the 8 taxa not evaluated in 2000, one categorized Not Threatened, 4 Insufficiently Known, one Vulnerable, and 2 Threatened. These changes are the result of: (1) increased systematic, biogeographical and bio- ecological information available for the evaluation, (2) Changes in human pressures on the species or their habitats, (3) methodological changes that included recommendations to apply concepts, discussion and consensus among specialists and the analysis of uncertainties.Asociación Herpetológica Argentina (AHA

Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases

Objective: This paper points out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients affected by Undifferentiated Systemic AutoInflammatory Diseases (USAIDs). Methods: This is an electronic registry employed for real-world data collection about demographics, clinical, laboratory, instrumental and socioeconomic data of USAIDs patients. Data recruitment, based on the Research Electronic Data Capture (REDCap) tool, is designed to obtain standardized information for real-life research. The instrument is endowed with flexibility, and it could change over time according to the scientific acquisitions and potentially communicate with other similar tools; this platform ensures security, data quality and data governance. Results: The focus of the AIDA project is connecting physicians and researchers from all over the world to shed a new light on heterogeneous rare diseases. Since its birth, 110 centers from 23 countries and 4 continents have joined the AIDA project. Fifty-four centers have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 179 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry is collecting baseline and follow-up data using 3,769 fields organized into 23 instruments, which include demographics, history, symptoms, trigger/risk factors, therapies, and healthcare information access for USAIDs patients. Conclusions: The development of the AIDA International Registry for USAIDs patients will facilitate the online collection of real standardized data, connecting a worldwide group of researchers: the Registry constitutes an international multicentre observational groundwork aimed at increasing the patient cohort of USAIDs in order to improve our knowledge of this peculiar cluster of autoinflammatory diseases

Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments

The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations

Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's Disease

Introduction: The effectiveness of canakinumab may change according to the different times it is used after Still's disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.Methods: Patients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease. Seventy-seven (51 females and 26 males) patients with Still's disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.Results: No statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.Conclusion: Canakinumab has proved to be effective in patients with Still's disease, regardless of its line of biologic treatment

Development and Implementation of the AIDA International Registry for Patients With Still's Disease

Objective: Aim of this paper is to present the design, construction, and modalities of dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which are the pediatric and adult forms of the same autoinflammatory disorder. Methods: This Registry is a clinical, physician-driven, population- and electronic-based instrument implemented for the retrospective and prospective collection of real-world data. The collection of data is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain evidence drawn from routine patients' management. The collection of standardized data is thought to bring knowledge about real-life clinical research and potentially communicate with other existing and future Registries dedicated to Still's disease. Moreover, it has been conceived to be flexible enough to easily change according to future scientific acquisitions. Results: Starting from June 30th to February 7th, 2022, 110 Centers from 23 Countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 4449 fields organized into 14 instruments, including patient's demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. Conclusions: This international Registry for patients with Still's disease will allow a robust clinical research through collection of standardized data, international consultation, dissemination of knowledge, and implementation of observational studies based on wide cohorts of patients followed-up for very long periods. Solid evidence drawn from "real-life " data represents the ultimate goal of this Registry, which has been implemented to significantly improve the overall management of patients with Still's disease. NCT 05200715 available at

Clinical and laboratory features associated with macrophage activation syndrome in Still's disease: data from the international AIDA Network Still's Disease Registry

: To characterize clinical and laboratory signs of patients with still's disease experiencing macrophage activation syndrome (MAS) and identify factors associated with MAS development. patients with still's disease classified according to internationally accepted criteria were enrolled in the autoInflammatory disease alliance (AIDA) still's disease registry. clinical and laboratory features observed during the inflammatory attack complicated by MAS were included in univariate and multivariate logistic regression analysis to identify factors associated to MAS development. A total of 414 patients with Still's disease were included; 39 (9.4%) of them developed MAS during clinical history. At univariate analyses, the following variables were significantly associated with MAS: classification of arthritis based on the number of joints involved (p = 0.003), liver involvement (p = 0.04), hepatomegaly (p = 0.02), hepatic failure (p = 0.01), axillary lymphadenopathy (p = 0.04), pneumonia (p = 0.03), acute respiratory distress syndrome (p < 0.001), platelet abnormalities (p < 0.001), high serum ferritin levels (p = 0.009), abnormal liver function tests (p = 0.009), hypoalbuminemia (p = 0.002), increased LDH (p = 0.001), and LDH serum levels (p < 0.001). at multivariate analysis, hepatomegaly (OR 8.7, 95% CI 1.9-52.6, p = 0.007) and monoarthritis (OR 15.8, 95% CI 2.9-97.1, p = 0.001), were directly associated with MAS, while the decade of life at Still's disease onset (OR 0.6, 95% CI 0.4-0.9, p = 0.045), a normal platelet count (OR 0.1, 95% CI 0.01-0.8, p = 0.034) or thrombocytosis (OR 0.01, 95% CI 0.0-0.2, p = 0.008) resulted to be protective. clinical and laboratory factors associated with MAS development have been identified in a large cohort of patients based on real-life data

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Background and objectives: It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19-related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population. Methods: Hospitalization, intensive care unit (ICU) admission, and death after COVID-19 diagnosis of 1,362 patients with MS were compared with the age- and sex-matched Italian population in a retrospective observational case-cohort study with population-based control. The observed vs the expected events were compared in the whole MS cohort and in different subgroups (higher risk: Expanded Disability Status Scale [EDSS] score > 3 or at least 1 comorbidity, lower risk: EDSS score ≤ 3 and no comorbidities) by the χ2 test, and the risk excess was quantified by risk ratios (RRs). Results: The risk of severe events was about twice the risk in the age- and sex-matched Italian population: RR = 2.12 for hospitalization (p < 0.001), RR = 2.19 for ICU admission (p < 0.001), and RR = 2.43 for death (p < 0.001). The excess of risk was confined to the higher-risk group (n = 553). In lower-risk patients (n = 809), the rate of events was close to that of the Italian age- and sex-matched population (RR = 1.12 for hospitalization, RR = 1.52 for ICU admission, and RR = 1.19 for death). In the lower-risk group, an increased hospitalization risk was detected in patients on anti-CD20 (RR = 3.03, p = 0.005), whereas a decrease was detected in patients on interferon (0 observed vs 4 expected events, p = 0.04). Discussion: Overall, the MS cohort had a risk of severe events that is twice the risk than the age- and sex-matched Italian population. This excess of risk is mainly explained by the EDSS score and comorbidities, whereas a residual increase of hospitalization risk was observed in patients on anti-CD20 therapies and a decrease in people on interferon